All In Biotech

Drug Trial Radar · NCT05057169

Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

451

Actual

Start

Nov 18, 2021

Primary completion

Dec 31, 2024

Study completion Dec 31, 2025

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized comparison of 3rd dose with inactivated vaccine (CoronaVac) or mRNA vaccine (Comirnaty) in adults who previously received two doses of CoronaVac (Sinovac) or two doses of BNT162b2 (Comirnaty, BioNTech/Fosun Pharma) at least 6 months earlier.

Conditions

  • COVID-19 Vaccination

Interventions

  • BNT162b2Biological

    BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.

  • CoronaVacBiological

    CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing antibodiesTime frame: 28 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Hong Kong

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.